Kenvue Inc.
$ 19.22
0.21%
07 Aug - close price
- Market Cap 36,825,768,000 USD
- Current Price $ 19.22
- High / Low $ 19.27 / 18.87
- Stock P/E 22.83
- Book Value 5.62
- EPS 0.84
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date 2026-08-26
- ROA 0.07 %
- ROE 0.16 %
- 52 Week High 21.18
- 52 Week Low 13.53
About
Kenvue Inc. is a consumer health company globally.
Analyst Target Price
$19.83
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-05-07 | 2026-02-17 | 2025-11-03 | 2025-08-07 | 2025-05-08 | 2025-02-06 | 2024-11-07 | 2024-08-06 | 2024-05-07 | 2024-02-08 | 2023-10-26 |
| Reported EPS | 0.31 | 0.32 | 0.27 | 0.28 | 0.29 | 0.24 | 0.26 | 0.28 | 0.32 | 0.28 | 0.31 | 0.31 |
| Estimated EPS | 0.32 | 0.26 | 0.22 | 0.26 | 0.28 | 0.23 | 0.26 | 0.27 | 0.28 | 0.25 | 0.28 | 0.31 |
| Surprise | -0.01 | 0.06 | 0.05 | 0.02 | 0.01 | 0.01 | 0 | 0.01 | 0.04 | 0.03 | 0.03 | 0 |
| Surprise Percentage | -3.125% | 23.0769% | 22.7273% | 7.6923% | 3.5714% | 4.3478% | 0% | 3.7037% | 14.2857% | 12% | 10.7143% | 0% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Aug 2026 | May 2026 | Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-08-26 | 2026-05-27 | 2026-02-25 | 2025-11-26 | 2025-08-27 | 2025-05-28 | 2025-02-26 | 2024-11-27 | 2024-08-28 | 2024-05-22 |
| Amount | $0.21 | $0.2075 | $0.2075 | $0.2075 | $0.2075 | $0.205 | $0.205 | $0.205 | $0.205 | $0.2 |
Next Dividend Records
| Dividend per share (year): | N/A |
| Dividend Yield | 0% |
| Next Dividend Date | 2026-08-26 |
| Ex-Dividend Date | 2026-08-12 |
Recent News: KVUE
2026-08-08 07:38:11
Wall Street Zen has downgraded Kenvue (NYSE:KVUE) from a "Buy" to a "Hold" rating, reflecting a consensus among analysts. The company's second-quarter revenue grew 3% year-over-year to $3.96 billion, but EPS and revenue slightly missed expectations due to inflationary pressures, tariffs, and currency costs. Institutional investors hold a significant 97.64% stake in Kenvue, and a Kimberly-Clark transaction is anticipated to close in Q4 2026.
2026-08-08 07:38:10
Assenagon Asset Management S.A. significantly reduced its stake in Kenvue Inc. (NYSE:KVUE) by 49.8% in the second quarter, selling 3.19 million shares and retaining 3.22 million shares. This move comes as Kenvue reported Q2 sales of $3.96 billion and adjusted EPS of $0.31, both slightly missing analyst estimates due to inflationary pressures and currency costs. Despite the mixed financial results and a pending transaction with Kimberly-Clark, analysts maintain an overall "Hold" rating on the stock, with the company offering a 4.4% annualized dividend yield.
2026-08-07 15:08:16
Kimberly-Clark is preparing for its acquisition of Kenvue by consolidating 6,000 applications and over 15 ERP systems, aiming for significant cost savings and operational efficiencies. The company plans to integrate supply chain and commercial operations, standardize IT infrastructure, and deploy AI across various functions. These efforts are part of a broader digital transformation to optimize operations and achieve $1.9 million in savings over three years.
2026-08-07 13:38:21
Kenvue reported 3% revenue growth and 7% adjusted EPS growth in the second quarter, driven by 0.7% volume growth despite muted performance in the US and Europe. This volume growth was a rare achievement for the company. Morningstar highlighted this positive performance in their analyst note.
2026-08-07 08:56:21
Janus Henderson Group PLC increased its stake in Kenvue Inc. (NYSE:KVUE) by 45.6% during the first quarter, purchasing 110,155 additional shares to bring its total holding to 351,873 shares valued at approximately $6.1 million. While institutional investors own 97.64% of Kenvue, the company's second-quarter results saw sales increase by 3.0% to $3.96 billion and adjusted EPS rise to $0.31, though both figures slightly missed analyst estimates due to inflationary and foreign-exchange pressures. Kenvue maintains a "Hold" rating from analysts with an average price target of $19.58, declared a quarterly dividend of $0.21, and its acquisition by Kimberly-Clark is expected to close in Q4 2026.
2026-08-07 07:38:35
Kenvue Inc. (KVUE) is the world's largest pure-play consumer health company, having spun off from Johnson & Johnson in May 2023. Recent earnings show rare volume growth despite muted performance in the US and Europe. Analysts continue to evaluate its market position and financial outlook.
